Latest news

FDA greenlights first-ever Barth syndrome drug after decade-long push

FDA greenlights first-ever Barth syndrome drug after decade-long push

Eduardo Longoria
Daily Snap - 19. September 2025

Daily Snap - 19. September 2025

Joachim Eeckhout
VectorY inks $1.2B deal to boost brain-targeted gene therapy with Shape's delivery tech

VectorY inks $1.2B deal to boost brain-targeted gene therapy with Shape's delivery tech

Eduardo Longoria
Roche bets $2.4B on potential MASH breakthrough with 89bio buy

Roche bets $2.4B on potential MASH breakthrough with 89bio buy

Eduardo Longoria
Daily Snap - 18. September 2025

Daily Snap - 18. September 2025

Joachim Eeckhout
Aditum Bio bets $1B on siRNA breakthrough in heart disease

Aditum Bio bets $1B on siRNA breakthrough in heart disease

Eduardo Longoria
Ollin Biosciences takes aim at Roche with $100M and bold eye drug strategy

Ollin Biosciences takes aim at Roche with $100M and bold eye drug strategy

Eduardo Longoria
Daily Snap - 17. September 2025

Daily Snap - 17. September 2025

Joachim Eeckhout
Genmab axes ADC from $1.8B ProfoundBio buyout over safety concerns

Genmab axes ADC from $1.8B ProfoundBio buyout over safety concerns

Eduardo Longoria
Apollo's $15M eczema gamble pays off with promising phase 2 win

Apollo's $15M eczema gamble pays off with promising phase 2 win

Eduardo Longoria
Daily Snap - 16. September 2025

Daily Snap - 16. September 2025

Joachim Eeckhout
Novartis expands $5.7B bet on Monte Rosa’s protein-degrading drugs

Novartis expands $5.7B bet on Monte Rosa’s protein-degrading drugs

Eduardo Longoria
FirstBack
1213141516171819
Next Last